FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to biotechnology and medicine. Disclosed is a method of treating non-small cell lung cancer in a subject, comprising administering to a subject a therapeutically effective amount of a PD-1 receptor and its PD-L1 receptor interaction inhibitor. Inhibitor is an anti-PD-L1 antibody which comprises three complementarity determining regions (CDR) in a heavy chain and a light chain according to the given amino acid sequences. Such an antibody in one of the embodiments is avelumab.
EFFECT: use of the invention confirms the effect and clinical effectiveness of avelumab in relation to the patients suffering from non-small-cell lung cancer, which can solve the problem of providing safe and effective treatment of non-small-cell lung cancer.
9 cl, 2 dwg, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| USE OF ANTI-PD-1 ANTIBODY IN PREPARATION OF MEDICINAL AGENT FOR TREATING SOLID TUMOURS | 2020 |
|
RU2825845C2 |
| COMBINATION OF ANTI-PD-L1 ANTIBODY AND DNA-PK INHIBITOR FOR TREATING MALIGNANT NEOPLASM | 2018 |
|
RU2765997C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
| ANTIBODIES TO PD-1(CD279) | 2017 |
|
RU2752562C2 |
| COMBINATION OF PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER | 2016 |
|
RU2737216C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| DOSING REGIMENS WITH INTRODUCTION OF BISPECIFIC ANTIBODIES AGAINST LAG-3/PD-L1 | 2020 |
|
RU2818587C2 |
| USE OF COMBINATION OF ANTIBODY TO PD-1 AND VEGFR INHIBITOR IN PRODUCTION OF DRUG FOR TREATMENT OF MALIGNANT NEOPLASMS | 2017 |
|
RU2762746C2 |
| MOLECULES OF ANTIBODIES TO PD-1 AND THEIR USE | 2016 |
|
RU2788092C2 |
